New Perspectives in Autoimmune & Metabolic Disease Diagnostics – YHLO Workshop at EuroMedLab
From May 18–22, 2025, the 26th EuroMedLab Congress was successfully held at Brussels Expo in Belgium. Jointly organized by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), EuroMedLab is one of the most influential global congresses in the field of laboratory medicine. This year’s event gathered over 5,000 experts, clinicians, and IVD industry leaders from more than 100 countries to explore the latest developments and future directions in laboratory medicine.
As a leading IVD enterprise from China, YHLO made a strong impression at the event, showcasing its comprehensive diagnostic solutions in autoimmune diseases, metabolic disorders, cardiovascular health, and more. With its diversified technological platforms and robust global service network, YHLO’s booth quickly became a focal point, drawing interest from clinical experts, researchers, and global partners and highlighting the growing international influence of Chinese diagnostics innovation.
A key highlight of YHLO’s participation was its official academic workshop held on May 21, titled “Driving Diagnostic Innovation: New Perspectives in Autoimmune and Metabolic Diseases.” The event brought together nearly 150 participants, including leading clinicians, scientists, and diagnostic professionals, to explore emerging technologies and their clinical applications.
The workshop was moderated by Prof. T. Trenti and featured insightful presentations by Prof. E. Bosi of Vita-Salute San Raffaele University and Prof. P. Formisano of the University of Naples Federico II. The workshop concluded with a presentation by Ms. Juan Peng, Senior Marketing Manager at YHLO, who shared the company’s recent advancements in antiphospholipid syndrome (APS) diagnostics.
Since its founding in 2008, YHLO has established a synergistic development system centered on chemiluminescence, immunoblot, and indirect immunofluorescence platforms. Its product portfolio spans key diagnostic areas including autoimmune diseases, reproductive health, diabetes, liver conditions, infectious diseases, and cardiovascular disorders. With a strategy that emphasizes academic leadership, YHLO actively collaborates with leading universities, research institutions, and medical centers to promote both clinical research and translational development, continually deepening its technological capabilities and industry impact.
Looking ahead, YHLO remains committed to increasing its investment in innovation and R&D, expanding the applications of frontier diagnostics, and accelerating the clinical translation of scientific breakthroughs. Through high-precision and efficient testing solutions, YHLO will continue to serve the global healthcare community and elevate the role of “Intelligent Manufacturing in China” in safeguarding human health worldwide.
Attachments:
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
